全国免费电话:400-668-6834 -- 仅限中国地区 -- |
在线订购:QQ: 4006686834 电话订购:021-68591985 邮件订购:info@selleck.cn 我们也提供销售人员上门服务 |
技术支持电话:400-168-6834 我们将于一个工作日与您联系 |
目录号:A2005 批次号: A200510
Pembrolizumab (anti-PD-1)是一种有效的、高选择性的、人源IgG4-kappa单克隆抗体,同时也是抑制剂,靶向PD-1,具有潜在的免疫检查点抑制活性和抗肿瘤活性;MW:146.286 KD。
CAS号 | 1374853-91-4 |
---|---|
配制 | PBS buffer, pH 7.2 |
推荐同型对照 | Human IgG4 |
来源 | CHO cells |
储存条件 (自收到货起) |
Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles |
纯度 | 99% |
蛋白浓度 | 12.407mg/ml |
内毒素 | <1EU/mg |
IL-4 mediated TAP2 downregulation is a dominant and reversible mechanism of immune evasion and immunotherapy resistance in non-small cell lung cancer [ Mol Cancer, 2025, 24(1):80] | PubMed: 40091029 |
Tebentafusp, a T cell engager, promotes macrophage reprogramming and in combination with IL-2 overcomes macrophage immunosuppression in cancer [ Nat Commun, 2025, 16(1):2374] | PubMed: 40064880 |
Increased PD-1 expression in livers associated with PD-1-antibody-induced hepatotoxicity [ BMC Immunol, 2025, 26(1):4] | PubMed: 39844069 |
Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial [ Nat Med, 2024, 10.1038/s41591-024-02824-y] | PubMed: 38374347 |
Chemotherapy induces myeloid-driven spatially confined T cell exhaustion in ovarian cancer [ Cancer Cell, 2024, 42(12):2045-2063.e10] | PubMed: 39658541 |
The BCL-2 inhibitor APG-2575 resets tumor-associated macrophages toward the M1 phenotype, promoting a favorable response to anti-PD-1 therapy via NLRP3 activation [ Cell Mol Immunol, 2024, 21(1):60-79] | PubMed: 38062129 |
Multi-omic profiling reveals the endogenous and neoplastic responses to immunotherapies in cutaneous T cell lymphoma [ Cell Rep Med, 2024, S2666-3791(24)00196-4] | PubMed: 38670099 |
Miltefosine reinvigorates exhausted T cells by targeting their bioenergetic state [ Cell Rep Med, 2024, 5(12):101869] | PubMed: 39657666 |
Favorable impact of PD1/PD-L1 antagonists on bone remodeling: an exploratory prospective clinical study and ex vivo validation [ J Immunother Cancer, 2024, 12(5)e008669] | PubMed: 38702145 |
Decoupling FcRn and tumor contributions to elevated immune checkpoint inhibitor clearance in cancer cachexia [ Pharmacol Res, 2024, 199:107048] | PubMed: 38145833 |
禁止用于人体及治疗!